Bacil Pharma [BACPHAR] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison
Bacil Pharma
BSE
Loading...
Aarti Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Bacil Pharma wins in 6 metrics, Aarti Drugs wins in 11 metrics, with 0 ties. Aarti Drugs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bacil Pharma | Aarti Drugs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 30.00 | 22.73 | Aarti Drugs |
| Price-to-Book Ratio | 1.13 | 3.13 | Bacil Pharma |
| Debt-to-Equity Ratio | 0.64 | 44.92 | Bacil Pharma |
| PEG Ratio | -0.03 | 0.36 | Bacil Pharma |
| EV/EBITDA | -153.41 | 16.50 | Bacil Pharma |
| Profit Margin (TTM) | 111.61% | 7.80% | Bacil Pharma |
| Operating Margin (TTM) | -10.86% | 10.11% | Aarti Drugs |
| EBITDA Margin (TTM) | N/A | 10.11% | N/A |
| Return on Equity | 1.59% | 12.28% | Aarti Drugs |
| Return on Assets (TTM) | 1.58% | 6.53% | Aarti Drugs |
| Free Cash Flow (TTM) | $4.01M | $674.20M | Aarti Drugs |
| Dividend Yield | N/A | 0.22% | N/A |
| 1-Year Return | 92.79% | -19.43% | Bacil Pharma |
| Price-to-Sales Ratio (TTM) | 21.92 | 1.77 | Aarti Drugs |
| Enterprise Value | $487.13M | $48.78B | Aarti Drugs |
| EV/Revenue Ratio | 49.12 | 2.01 | Aarti Drugs |
| Gross Profit Margin (TTM) | N/A | 36.77% | N/A |
| Revenue per Share (TTM) | $1 | $265 | Aarti Drugs |
| Earnings per Share (Diluted) | $1.23 | $20.66 | Aarti Drugs |
| Beta (Stock Volatility) | 0.30 | 0.21 | Aarti Drugs |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Bacil Pharma vs Aarti Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bacil Pharma | -1.60% | -1.60% | -1.81% | -11.19% | -11.53% | -30.72% |
| Aarti Drugs | -0.17% | -2.79% | -12.89% | -0.75% | 33.64% | 3.08% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bacil Pharma | 92.79% | 766.20% | 1,146.62% | 476.56% | 638.00% | 246.48% |
| Aarti Drugs | -19.43% | 7.76% | -34.26% | 253.58% | 2,521.72% | 2,340.49% |
Performance & Financial Health Analysis: Bacil Pharma vs Aarti Drugs
| Metric | BACPHAR | AARTIDRUGS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹217.34M | ₹42.86B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 29,436 | 154,237 |
| 90 Day Avg. Volume | 31,562 | 308,438 |
| Last Close | ₹36.90 | ₹469.55 |
| 52 Week Range | ₹16.24 - ₹62.56 | ₹312.00 - ₹604.35 |
| % from 52W High | -41.02% | -22.30% |
| All-Time High | ₹62.56 (Dec 16, 2024) | ₹1,026.95 (Oct 05, 2020) |
| % from All-Time High | -41.02% | -54.28% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.06% |
| Quarterly Earnings Growth | N/A | 0.62% |
| Financial Health | ||
| Profit Margin (TTM) | 1.12% | 0.08% |
| Operating Margin (TTM) | -0.11% | 0.10% |
| Return on Equity (TTM) | 0.02% | 0.12% |
| Debt to Equity (MRQ) | 0.64 | 44.92 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹32.60 | ₹149.84 |
| Cash per Share (MRQ) | ₹2.05 | ₹2.48 |
| Operating Cash Flow (TTM) | ₹4.03M | ₹2.83B |
| Levered Free Cash Flow (TTM) | ₹4.04M | ₹1.68B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.22% |
| Last 12-Month Dividend | N/A | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Bacil Pharma vs Aarti Drugs
| Metric | BACPHAR | AARTIDRUGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 30.00 | 22.73 |
| Forward P/E | N/A | 14.45 |
| PEG Ratio | -0.03 | 0.36 |
| Price to Sales (TTM) | 21.92 | 1.77 |
| Price to Book (MRQ) | 1.13 | 3.13 |
| Market Capitalization | ||
| Market Capitalization | ₹217.34M | ₹42.86B |
| Enterprise Value | ₹487.13M | ₹48.78B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 49.12 | 2.01 |
| Enterprise to EBITDA | -153.41 | 16.50 |
| Risk & Other Metrics | ||
| Beta | 0.30 | 0.21 |
| Book Value per Share (MRQ) | ₹32.60 | ₹149.84 |
Financial Statements Comparison: Bacil Pharma vs Aarti Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BACPHAR | AARTIDRUGS |
|---|---|---|
| Revenue/Sales | ₹0 | ₹6.77B |
| Cost of Goods Sold | N/A | ₹4.37B |
| Gross Profit | N/A | ₹2.40B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-1.09M | ₹784.50M |
| EBITDA | ₹-1.09M | ₹951.90M |
| Pre-Tax Income | ₹8.94M | ₹711.50M |
| Income Tax | ₹2.25M | ₹83.80M |
| Net Income (Profit) | ₹6.69M | ₹627.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BACPHAR | AARTIDRUGS |
|---|---|---|
| Cash & Equivalents | ₹28.57M | ₹45.80M |
| Total Current Assets | ₹29.08M | ₹13.38B |
| Total Current Liabilities | ₹1.69M | ₹8.37B |
| Long-Term Debt | N/A | ₹2.86B |
| Total Shareholders Equity | ₹254.31M | ₹13.69B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | N/A | ₹8.59B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BACPHAR | AARTIDRUGS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BACPHAR | AARTIDRUGS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 29,436 | 154,237 |
| Average Daily Volume (90 Day) | 31,562 | 308,438 |
| Shares Outstanding | 5.89M | 91.27M |
| Float Shares | 12.10M | 35.46M |
| % Held by Insiders | 0.15% | 0.60% |
| % Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Bacil Pharma vs Aarti Drugs
| Metric | BACPHAR | AARTIDRUGS |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹1.00 |
| Last 12-Month Dividend Yield | N/A | 0.22% |
| 3-Year Avg Annual Dividend | N/A | ₹1.00 |
| 3-Year Avg Dividend Yield | N/A | 0.23% |
| 3-Year Total Dividends | N/A | ₹3.00 |
| Ex-Dividend Date | N/A | Feb 04, 2025 |